Despite legalizing medical cannabis eight years ago, Peru has established patient registries, authorized products, licensed pharmacies, and pathways for associative cultivation. However, a DIGEMID analysis reveals that much of this regulatory framework has not translated into actual product availability in the formal market. This gap between regulatory structure and real-world access represents a significant challenge for patients with qualifying conditions seeking cannabinoid-based treatments. The findings highlight the importance of bridging policy implementation with functional supply chains to serve patients effectively.
